Long-term tralokinumab therapy in moderate to severe atopic dermatitis

被引：0
|
作者：
Lorenz, Judith
机构：
来源：
AKTUELLE DERMATOLOGIE | 2023年 / 49卷 / 03期
关键词：
D O I：
10.1055/a-1974-5392
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [31] Long-Term Safety, Efficacy, and Adherence of Tralokinumab for the Treatment of Patients with moderate to severe atopic Dermatitis over a Period of up to 3 Years: Interim Analysis of ECZTEND, a Phase III Long-Term Extension Study
    Wollenberg, Andreas
    Blauvelt, Andrew
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Herranz, Pedro
    Pink, Andrew
    Peris, Ketty
    Saeki, Hidehisa
    Beissert, Stefan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 19 - 20
  • [32] Long-term follow-up in patients with moderate-to-severe atopic dermatitis treated with dupilumab
    Votto, M.
    Fortina, V.
    De Filippo, M.
    Naso, M.
    Villanova, M.
    Licari, A.
    Marseglia, G. L.
    Brazzelli, V.
    ALLERGY, 2023, 78
  • [33] PATIENT PERCEPTION OF TREATMENT WITH LONG-TERM DUPILUMAB MONOTHERAPY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Simpson, E.
    Lacour, J.
    Beck, L.
    Zhang, H.
    Aamodt, K.
    Rossi, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S55 - S56
  • [34] Tralokinumab in atopic dermatitis
    Wollenberg, Andreas
    Weidinger, Stephan
    Worm, Margitta
    Bieber, Thomas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (10): : 1435 - 1442
  • [35] Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
    Weidinger, Stephan
    Bewley, Anthony
    Hong, H. Chih-ho
    Silvestre, Juan Francisco
    Peris, Ketty
    Wollenberg, Andreas
    Ivens, Ulla
    Soehoel, Anders
    Steffensen, Louise Abildgaard
    Tindberg, Ann-Marie
    Simpson, Eric L.
    BRITISH JOURNAL OF DERMATOLOGY, 2025, 192 (03) : 410 - 419
  • [36] A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults
    Pezzolo, Elena
    Sechi, Andrea
    Tartaglia, Jacopo
    Naldi, Luigi
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (03) : 255 - 266
  • [37] Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
    Blauvelt, Andrew
    Pink, Andrew
    Worm, Margitta
    Langley, Richard G. B.
    Elewski, Boni E.
    Le Gjerum
    Guttman-Yassky, Emma
    JAMA DERMATOLOGY, 2022, 158 (11) : 1327 - 1330
  • [38] Progressive and sustained improvements in the extent and severity of atopic dermatitis with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis
    Alexis, A. F.
    Zirwas, M.
    Pinter, A.
    Adam, D. N.
    Chiricozzi, A.
    Pink, A. E.
    Mark, T.
    Tindberg, A. M.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E82 - E83
  • [39] Mycophenolate mofetil therapy for moderate to severe atopic dermatitis
    Murray, M. L.
    Cohen, J. B.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2007, 32 (01) : 23 - 27
  • [40] Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis
    Nicol, Noreen Heer
    Boguniewicz, Mark
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (01) : 123 - +
12345